Cytori Receives IDE Approval from FDA to Initiate US Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries

Cytori Therapeutics (NASDAQ: CYTX ) has received Investigational Device Exemption (IDE) approval from the FDA to begin a prospective clinical trial to evaluate the safety and feasibility of